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Background: Urinary steroid metabolite ratios may improve the diagnostic yield of potential disorders of steroid
hormone synthesis.
Objectives: To investigate the range of ratios and their predictive value in children with suspected disorders of
steroid synthesis.
Design and methods: Twelve ratios were calculated on steroid metabolite data analysed by gas
chromatography–mass spectrometry in urine samples collected between 2008–2010 from 93 children. Urine
samples were also analysed in 252 children with no known endocrine concerns.
Results: Of the 252 controls, 115 (46%) were male with a median age of 10 yr (range 1 month,18.5 years). Of the 93
cases, 38 (41%) were male with a median age of 6.5 yr (1 day,18.5 yrs). Of these, 41 (44%) had at least one ratio
greater than the 95% percentile for controls. The most frequently abnormal ratio, found in 18/93 (19%) cases was
(THS/(THE + THF + 5αTHF)) suggestive of 11β-hydroxylase deficiency. Over this period, 8 (9%) children were
subsequently diagnosed with a steroid hormone disorder; 4 with 21-hydroxylase deficiency, 2 with11β-hydroxylase
deficiency and 2 with 5α-reductase deficiency. All except one of these children had at least 1 raised ratio.
Conclusions: Urinary steroid metabolite ratios in suspected disorders of hormone synthesis often exceed the
reference range for normal children. The predictive value of steroid metabolite ratios in identifying a genetic
abnormality may be condition specific and needs further study to improve its clinical utility.
Keywords: Urine, Disorders of sex developmentIntroduction
Assessment of urinary steroid metabolite excretion is re-
ported to be a valuable tool in the investigation of disorders
of steroid hormone synthesis as it offers the opportunity to
simultaneously examine many different steroids [1,2]. It is
non-invasive, avoids the need for multiple blood tests and
may provide reliable information on spot urine samples.
The standard method of analysing urinary steroid metabo-
lites involves gas chromatography/mass spectrometry (GC-* Correspondence: faisal.ahmed@glasgow.ac.uk
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unless otherwise stated.MS) [3]. Given that individual metabolite concentrations
will be altered depending on the level of the enzyme block,
the calculation of a urinary steroid metabolite ratio (uSMR)
using GC-MS steroid profile results may be a particularly
valuable method of improving diagnostic yield when investi-
gating such disorders [4,5]. However, reference ranges for
these ratios are not widely available and it is unclear whether
such ratios need to be age and sex matched. In addition, as
individual biosynthetic disorders may be associated with an
abnormality of multiple ratios the clinical utility of calculat-
ing ratios in the diagnostic pathway remains unclear.
The aims of this study were, therefore, to determine
reference ranges for a range of urinary steroid ratios andentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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childhood population under investigation for suspected
disorders of steroid synthesis.
Subjects & methods
Of a total of 127 urinary steroid profiles collected
between 2008 and 2010 at a single children’s hospital, 31
(24%) cases were excluded as they were 19 years old or
over, were undergoing a dexamethasone suppression test
or a synacthen stimulation test or were on steroid
replacement therapy. Of the 96 eligible cases, sufficient
clinical information was unavailable in 3. Of the
remaining 93 cases, 38 (41%) were male and the median
age at the time of the test was 6.5 years (range 1 day,
18.5 years). A total of 17 cases (18%) were <6 months at
the time of test; 60 (65%) were 6 months-10 years of age
and 16 (17%) were >10 years of age at the time of test.
A review of the clinical records was conducted
for all cases to confirm the clinical characteristics,
diagnosis and outcome. Of the 93 cases, indications
for assessment of urinary steroid profile included early
signs of puberty in 21 (22%), adrenarche in 16 (17%),
suspected disorder of sex development in 10 (11%),
congenital adrenal hyperplasia in 8 (9%) and Cushing’s
syndrome in 2 (2%). In the remaining 36 (39%) cases,
no clear reason for the test was available in the
clinical records.
Urine samples from two groups of children were col-
lected to develop a reference range. The first group con-
sisted of 96 children with no background of endocrine
concerns who had a urine sample collected at presenta-
tion for investigation of an acute systemic illness. EightTable 1 Urinary steroid ratios and the number of cases with a
Ratio Cases analysed
out of 93
Cases >95th
percentile
Cases of s
disorder w
percentile
ratio >95t
17HP/(THE + THF + 5αTHF) 93 (100%) 18 4 (22%)
PT/(THE + THF + 5αTHF) 92 (99%) 16 4 (25%)
PTONE/(THE + THF + 5αTHF) 61 (65%) 11 5 (45%)
THS/(THE + THF + 5αTHF) 92 (99%) 23 4(17%)
DHEA/(THE + THF + 5αTHF) 90 (96%) 12 2 (17%)
(17HP + PT)/(An + Et) 85 (90%) 6 2 (33%)
(THF + 5αTHF)/THE 93 (100%) 7 1 (14%)
THE/(THF + 5αTHF) 93 (100%) 9 1 (11%)
(An + Et)/(THE + THF + 5αTHF) 89 (95%) 6 1 (17%)
Et/An 84 (89%) 6 2 (33%)
THF/5αTHF 93 (100%) 10 2 (20%)
THB/5αTHB 86 (91%) 6 1 (17%)
17HP: 17-hydroxypregnanolone, PT: pregnanetriol, THE: tetrahydrocortisone, THF: te
DHEA: dehydroepiandrosteroone. PTONE: pregnanetriolone. THS: tetrahydro-11-deoxycor
5αTHB: 5α-tetrahydrocorticosterone.of these patients were excluded as they had a very high
urine free cortisol concentration >1000 nmol/l at the
time of urine sample. Urine samples were also collected
from 164 healthy school-age children. Of a total of 252
controls, 115 (46%) were male and the median age at
sample collection was 10 years (range 1 month-
18.5 years). The controls were broadly categorised into
three age bands <6 months, 6 months to 10 years and
more than 10 years.
The urinary steroid metabolite analysis was per-
formed by gas chromatography/mass spectrometry
(GC/MS) using the Thermo Scientific Trace Gas
Chromatography machine attached to an ITQ900
mass spectrometer. The method for analysis was a
modification of the method originally described by
Shackleton [6].
Twelve ratios as listed in Table 1 were calculated for
each case and control [5,6]. Table 2 demonstrates the
type of enzyme defect suggested by an abnormal ratio.
If samples had not been reported due to a technical
difficulty during analysis or there was insufficient sam-
ple for analysis and there was a lack of numerical data
to apply a ratio, they were excluded from analysis.
Table 1 demonstrates the number of cases analysed per
ratio. Medians and ranges were determined using
Microsoft Excel 2010 for all patients and controls.
Kruskal-Wallis tests were performed for all samples
using SPSS v 21 (IBM, 2013). Significance was deter-
mined if p ≤ 0.05.
The urine samples from the healthy school children
were collected following informed consent as part of a
previous study of growth and development that wasn abnormal ratio
uspected steroid
ith ratio >95th
(% of those with
h percentile)
Sensitivity Specificity Positive
predictive
value
Negative
predictive
value
100% 84% 22% 100%
100% 86% 25% 100%
100% 89% 45% 100%
100% 78% 17% 100%
100% 90% 17% 100%
100% 95% 33% 100%
100% 93% 14% 100%
100% 91% 11% 100%
100% 94% 17% 100%
100% 95% 33% 100%
100% 91% 20% 100%
100% 94% 17% 100%
trahydrocortisol. 5αTHF: 5a-tetrahydrocortisol. An:androsterone. Et: etiocholanolone.
tisol. THS: tetrahydro-11-deoxycortisol. THB: tetrahydrocorticosterone.
Table 2 Median, range and 95th centile for each urinary steroid metabolite ratio analysed for the whole group of
controls as well as categorised by broad age groups
All controls
N = 252
<6 months
N = 12
6 months-10 yrs
N = 106
>10 yrs
N = 134
Enzyme defect Median age 10 years 2 months 5 years 13 years
(Range) (11d-18 yrs) (11 d-5 m) (6 m-9 yrs) (10–18 yrs)
M:F ratio 115:137 7:5 47:59 61:73
21-Hydroxylase def 17HP/(THE + THF + 5αTHF)
Median (range) 0.01 (0–0.25) 0.01 (0.01-0.11) 0.01 (0–0.25) 0.01 (0–0.11)
95% centile 0.04 0.1 0.03 0.04
21-Hydroxylase def PT/(THE + THF + 5αTHF)
Median (range) 0.03 (0–0.48) 0.02 (0.01-0.03) 0.02 (0–0.28) 0.06 (0.01-0.48)
95% centile 0.13 0.03 0.09 0.15
21-Hydroxylase def PTONE/(THE + THF + 5αTHF)
Median (range) 0 (0–0.29) 0.01 (0–0.14) 0 (0–0.29) 0 (0–0.04)
95% centile 0.01 0.11 0.02 0.01
11β-Hydroxylase def THS/(THE + THF + 5αTHF)
Median (range) 0.01 (0–0.09) 0 (0–0.04) 0.01 (0–0.09) 0 (0–0.02)
95% centile 0.02 0.03 0.03 0.01
3β-Hydroxysteroid dehydrogenase def DHEA/(THE + THF + 5αTHF)
Median (range) 0 (0–1.25) 0.01 (0–0.1) 0 (0–1.25) 0 (0–0.31)
95% centile 0.12 0.1 0.03 0.14
P450 oxidoreductase def (17HP + PT)/(An + Et)
Median (range) 0.38 (0.1-12.5) 1.95 (0.5-5) 0.75 (0.17-12.5) 0.23 (0.1-0.75)
95% centile 3.18 4.52 3.93 0.46
Apparent mineralocorticoid excess (THF + 5αTHF)/THE
Median (range) 0.72 (0.01-7) 0.04 (0.01-0.35) 0.8 (0.15-7) 0.68 (0.25-.3.43)
95% centile 1.97 0.33 3.01 1.3
Apparent cortisone reductase deficiency THE/(THF + 5αTHF)
Median (range) 1.4 (0.16-88.69) 22.82 (2.87-88.69) 1.25 (0.16-20.9) 1.49 (0.29-20.7)
95% centile 3.84 86.58 2.39 3
17β-Hydroxysteroid
dehydrogenase deficiency
(An + Et)/(THE + THF + 5αTHF)
Median (range) 0.11 (0–1.65) 0.01 (0.01-0.09) 0.03 (0–0.75) 0.3 (0.04-1.65)
95% centile 0.7 0.07 0.23 0.9
5α-Reductase deficiency THF/5αTHF
Median (range) 0.73 (0.08-25.25) 0.96 (0.19-5) 0.68 (0.08-25.25) 0.83 (0.22-2)
95% centile 1.75 4.19 1.93 1.71
5α-Reductase deficiency THB/5αTHB
Median (range) 0.28 (0–68) 20.1 (0.33-68) 0.27 (0.02-47.64) 0.39 (0–2.05)
95% centile 3.89 53.06 1.97 1.24
5α-Reductase deficiency Et/An
Median (range) 0.59 (0.03-4.86) 0.13 (0.03-1) 0.56 (0.06-4.86) 0.64 (0.26-2.1)
95% centile 1.7 0.69 2 1.5
17HP: 17-hydroxypregnanolone, PT: pregnanetriol, THE: tetrahydrocortisone, THF: tetrahydrocortisol. 5αTHF: 5α-tetrahydrocortisol. An: androsterone. Et: etiocholanolone.
DHEA: dehydroepiandrosteroone. PTONE: pregnanetriolone. THS: tetrahydro-11-deoxycortisol. THB: tetrahydrocorticosterone. 5αTHB: 5α-tetrahydrocorticosterone.
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Table 3 Characteristics of confirmed cases
Sex Age Presenting features Biochemistry Ratios >95th percentile Actual ratio Diagnosis
M 5y Subclinical salt wasting Testosterone 5.1 17HP/(THE + THF + 5αTHF) 1.5 21-hydroxylase deficiency
Tall stature and sexual
precocity
17 OHP: 443 PT/(THE + THF + 5αTHF) 1.1 CYP21A2 mutation
Androstenedione NA PTONE/(THE + THF + 5αTHF) 11.5
THS/(THE + THF + 5αTHF) 0.04
DHEA/(THE + THF + 5αTHF) 0.14
(17HP + PT)/(An + Et) 15.1
(THF + 5αTHF)/THE 16.8
THB/5αTHB 5.3
M 10d Salt wasting presented with
vomiting and weight loss.
17 OHP: NA 17HP/(THE + THF + 5αTHF) 0.2 21-hydroxylase deficiency
Androstenedione NA PT/(THE + THF + 5αTHF) 0.5 CYP21A2 mutation
PTONE/(THE + THF + 5αTHF) 0.1
THE/(THF + 5αTHF) 62.3
F 13y Presented at 8 yrs with
exaggerated adrenarche.
Not salt wasting
17 OHP: 118 17HP/(THE + THF + 5αTHF) 0.3 21-hydroxylase deficiency
Androstenedione 11 PT/(THE + THF + 5αTHF) 0.2
PTONE/(THE + THF + 5αTHF) 0.1
DHEA/(THE + THF + 5αTHF) 0.7
F 3y Clitoromegaly with no
other signs of virilisation.
Not salt wasting
17 OHP 80 17HP/(THE + THF + 5αTHF) 18.6 21-hydroxylase deficiency
Androstenedione 30 PT/(THE + THF + 5αTHF) 37.2 CYP21A2 mutation
PTONE/(THE + THF + 5αTHF) 21.6
(17HP + PT)/(An + Et) 36.7
(An + Et)/(THE + THF + 5αTHF) 1.5
F 11y Premature adrenarche.
On steroid replacement.
Hypertensive.
17 OHP 3 THS/(THE + THF + 5αTHF) 0.1 11β-hydroxylase deficiency
Androstenedione 13.3
DOC – NA
F 2 m Clitoromegaly.
Hypertensive.
17 OHP: 3 THS/(THE + THF + 5αTHF) 0.6 11β-hydroxylase deficiency
Androstenedione < 1.4 PTONE/(THE + THF + 5αTHF) 0.02
M 8y Bilateral undescended
testes, micropenis.
DHT < 0.1 Nil 5α − reductase deficiency
Parents consanguineous Androstenedione 1.5
Testosterone 0.7
M 5y Glandular hypospadias. DHT < 0.1 THS/(THE + THF + 5αTHF) 0.04 5α − reductase deficiency
Parents consanguineous. Androstenedione 1.4 Et/An 5.1
Testosterone < 0.5 THF/5αTHF 31.8
USMR: Urinary steroid metabolite ratio. 17HP: 17-hydroxypregnanolone, PT: pregnanetriol, THE: tetrahydrocortisone, THF: tetrahydrocortisol. 5αTHF: 5α-tetrahydrocortisol.
An:androsterone. Et: etiocholanolone. DHEA: dehydroepiandrosteroone. PTONE: pregnanetriolone. THS: tetrahydro-11-deoxycortisol. THB: tetrahydrocorticosterone.
5αTHB: 5α-tetrahydrocorticosterone.
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additional samples that were collected from children
attending hospital were approved by the ethics service as
part of local assay development.Results
Table 2 demonstrates reference ranges for each of the
ratios. Analysis was performed to determine whether age
or gender influenced the results of the results of the
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urinary steroid metabolite ratios when categorised by
age and sex.
Of the 93 cases, 53 (57%) had ratios that were greater
than the 95% percentile for controls (Table 1). The num-
ber of ratios per case which were greater than the 95%
percentile for controls ranged from 0–8 (median 1). Of
these 53 cases with high ratios, 25 (47%), 10 (19%), 7
(13%) and 11 (21%) children had only 1, 2, 3 or >3 raised
ratios, respectively (Table 1).
The most commonly abnormal ratio when cases were
separated according to gender and compared with
controls was THS/(THE + THF + 5αTHF), with 20 of 53
(38%) cases having ratios greater than the 95% percentile
for controls. The most commonly abnormal ratio when
cases were separated according to age and compared to
controls was DHEA/(THE + THF + 5αTHF) with 19 of
53 (36%) cases. When cases were not split for either age
or gender, the most commonly abnormal ratio was THS/
(THE + THF + 5αTHF) which was greater than the 95%
percentile for controls in 24 of 93 (26%) cases.Figure 1 Urine steroid metabolite ratios for investigating 21-Hydroxy
possible cases and controls. Each confirmed case is a different shape to demoA total of 8 cases were subsequently diagnosed with a
steroid hormone disorder (true positives); 4 (44%) with
21-hydroxylase deficiency, 2 (22%) with 11β-hydroxylase
deficiency and 2 (22%) with 5α-reductase deficiency
(Table 3). All except one of these cases had at least 1 ra-
tio greater than the 95% percentile for controls. The case
with the normal steroid hormone ratios was later diag-
nosed with 5α-reductase deficiency. The median number
of abnormal ratios in the 4 cases with 21-hydroxylase
deficiency was 4.5 (range 4–6). All of these cases had ra-
tios greater than the 95% percentile for controls for the
3 ratios suggestive of 21-hydroxylase deficiency Figure 1).
Three of these patients had genetic confirmation of
CYP21A2 mutations. The other patient had been given
this diagnosis secondary to suggestive biochemistry re-
sults and clinical history. Genetic analysis had not been
performed for patients with any of the other disorders of
steroid synthesis.
The two cases of 11β-hydroxylase deficiency both
had a raised THS/(THE + THF + 5αTHF) ratio, which
is suggestive of 11β-hydroxylase deficiency (Figure 2).lase deficiency. Ratios for confirmed cases of 21-hydroxylase deficiency,
nstrate results of different ratios.
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premature adrenarche and had a repeat urine sample
at the age of 11 years. This patient had only one raised
ratio. The other presented with clitoromegaly at birth
and also had a raised PTONE/(THE + THF + 5αTHF)
ratio.
The 2 boys with 5α-reductase deficiency were 46,XY
brothers who presented with atypical genitalia. They had
consanguineous parents and were lost to follow-up be-
fore genetic investigations could be undertaken. One of
them had 3 abnormal ratios (THS/(THE + THF +
5αTHF), suggestive of 11β-hydroxylase deficiency and
Et/An and THF/5αTHF suggestive of 5α-reductase de-
ficiency) and presented with glandular hypospadias
and micropenis (Figure 2). His older brother who was
also affected had no abnormal urinary steroid ratios
and presented with bilateral undescended testes and
micropenis.
Discussion
Urinary steroid profiling is frequently performed in the
investigation of patients with suspected disorders of
steroid synthesis [7]. The clinical indication for this test
has also widened over the last few years. Steroid
profiling of maternal urine may be used as a method of
prenatal detection of conditions such as Smith Lemli
Opitz syndrome [8] and congenital adrenal hyperplasia
caused by P450 oxidoreductase deficiency (PORD), with
results suggesting that diagnostic steroid ratios couldFigure 2 Urine steroid metabolite ratios for investigating 11β-hydrox
cases of 11β-hydroxylase deficiency and 5α − reductase deficiency, possibledemonstrate PORD as early as at 12 weeks gestation [9].
Another recent study reviewed the use of urinary steroid
ratios in the differential diagnosis of PORD and classic
21-hydroxylase deficiency in Japanese children, finding
that the ratios were a reliable method of distinguishing
these 2 conditions [10]. The calculation of simple ratios
is thought to further improve the sensitivity and specifi-
city of the steroid profile in the detection of disorders of
steroid synthesis [5].
Our study provides references ranges for 12 steroid ra-
tios that have been highlighted as the ratios which may
be abnormally high in disorders of steroid synthesis [5].
The reference range was created from urine samples
collected from a range of sources and we have clearly
shown wide variations in urine steroid ratios in these
reference data. It is possible that some of these varia-
tions may be due to differences in the age and sex of the
child [11]. However, our data do not show a clear associ-
ation to these variables when assessing steroid metabol-
ite ratios indicating that these variations may only apply
to absolute values. It is possible that if the age categories
were over narrower age bands during childhood, then
some age and sex related differences in ratios as re-
ported before [12] may have been observed. It is also
possible that some of the children from whom samples
were obtained for creating the reference range had pre-
sented with an acute illness at the time of the urine sam-
ple and may have had raised steroid profiles secondary
to these illnesses. To mitigate this possibility, those casesylase deficiency and 5α − reductase deficiency. Ratios for confirmed
cases and controls.
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excluded. We have reported all the urine steroid ratios
in early infancy for completeness but we should high-
light that ratios for conditions such as 5α reductase
deficiency and apparent cortisone reductase deficiency
are difficult to interpret in early infancy.
We identified 8 children with a disorder of steroid
hormone synthesis. A total of 7 of these cases had ratios
greater than the 95% percentile for controls. Four of
these cases had confirmed 21-hydroxylase deficiency and
each of them had elevated ratios for the 3 ratios suggest-
ive of this condition. Only 1 other case in this study,
who had a sample collected at 18 days of age and was
born at 28 weeks gestation, had this combination of 3
ratios which were greater than the 95% percentile for
controls. For comparison, 6 other cases had ratios which
were greater than the 95% percentile for controls for
17HP/(THE + THF + 5αTHF) and PT/(THE + THF +
5αTHF) alone. It is, therefore, possible that for 21-
hydroxylase deficiency, genetic analysis could be rou-
tinely considered in those cases where all 3 ratios for
21-hydroxylase deficiency are raised. Depending on the
availability of local resources, an alternative strategy
would be to perform genetic analysis first and then
pursue urine steroid biochemistry in those cases which
do not reveal a gene mutation in CYP21A2.
Given that close to half of the cases had at least one
abnormal ratio and 19% had two or more abnormal ra-
tios, there is a need to clearly determine cut-offs regard-
ing the number of ratios that need to be abnormal or
the extent of abnormality that will prompt the need for
genetic analysis. The likelihood of detecting a gene mu-
tation, for instance in the CYP21A2 may be higher if all
three ratios are raised to a very high level but pub-
lished data supporting this, and its corollary, i.e. a low
likelihood of a gene mutation in cases where not all
ratios are mildly raised, are lacking. Our data also sug-
gest that identification of pathology should not solely
rely on steroid metabolite ratios. It is possible that a
particular change in a ratio could occur due to differ-
ent combinations of changes in its numerator and
denominator. It would, therefore, be important to also
pay attention to the absolute levels of the urine
metabolites.
Conclusions
In summary, several children who are investigated for a
disorder of steroid synthesis have urinary steroid metabolite
ratios that are above the reference range for normal healthy
children. Some ratios are more specific than others for
identifying disorders of androgen excess such as 21-
hydroxylase deficiency. The predictive value of single and
multiple steroid metabolite ratios in identifying a genetic
abnormality needs further exploration.Competing interests
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